Hope for a much-needed treatment for the common pregnancy complication pre-eclampsia has been raised by a successful test of ...

Plaque macrophage and endothelial cell content also increased disproportionately over controls. In order to confirm that the VEGF-mediated plaque progression was not species-specific, the ...

A new mRNA therapy tested in mice may target the root cause of the potentially fatal pregnancy disorder preeclampsia.

Aerosolized vascular endothelial growth factor/stromal cell-derived factor-1α (VEGFNP/SDFNP) led to a lower pulmonary arterial pressure and prevented right ventricular hypertrophy after monocrotaline ...

Whilst a persistent cough and coughing up blood is a sign something is wrong, another symptom that's often forgotten about is ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

Arteriovenous malformations, a hallmark of hereditary hemorrhagic telangiectasia, may be driven by endothelial cell-cycle ... Moreover, VEGF pathway overactivation has been suggested in HHT ...

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025LYTENAVA™ is the first and only approved ...

LM-299 is designed to target two key cancer-related molecules called programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). The PD-1/VEGF bispecific antibody is ...

Instil Bio is a clinical-stage biotech focusing on personalized immunotherapy. Check out my recommendation for TIL stock.